The complaint centers on allegations that Capricor violated the Securities Exchange Act of 1934 by disseminating false and misleading information. Specifically, the lawsuit claims the company altered its statistical analysis plan for the drug Deramiocel without prior FDA approval before resubmitting its Biologics License Application. This move reportedly obscured significant risks regarding the drug's effectiveness, ultimately causing investor losses when the market process uncovered the discrepancies.
Investors Face Deadline in Capricor Therapeutics Securities Litigation
Shareholders who acquired Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, face a September 28 deadline to seek lead plaintiff status in a pending class action lawsuit. The litigation, filed by Schall, Brown & Schwartz LLP, alleges the firm misled investors regarding its clinical data regulatory path.
Investors interested in the case may contact attorneys Brian Schall or David Schwartz at the Los Angeles-based firm. While the class has not yet been certified, those who incurred financial losses during the specified period are eligible to participate in the recovery efforts. Participation in the lawsuit does not require an appointment as a lead plaintiff, and shareholders who choose not to act remain absent class members until further legal developments occur.
Comments (0)
No comments yet. Be the first!